These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 26915749)
1. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749 [TBL] [Abstract][Full Text] [Related]
2. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483 [TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511 [TBL] [Abstract][Full Text] [Related]
4. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure. Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417 [TBL] [Abstract][Full Text] [Related]
5. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607 [TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan. Nomoto H; Satoh Y; Kamiyama M; Yabe K; Masumura M; Sakakibara A; Yamashita S; Suzuki M; Sugiyama T; Oumi T; Ohno M; Takahashi Y; Isobe M Int Heart J; 2017 Aug; 58(4):593-600. PubMed ID: 28701677 [TBL] [Abstract][Full Text] [Related]
8. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022 [TBL] [Abstract][Full Text] [Related]
9. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery. Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603 [TBL] [Abstract][Full Text] [Related]
10. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE; J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292 [TBL] [Abstract][Full Text] [Related]
11. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C; JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814 [TBL] [Abstract][Full Text] [Related]
12. Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure. Hirano D; Kakegawa D; Yamada A; Ito A; Miwa S; Ida H Pediatr Int; 2015; 57(1):183-5. PubMed ID: 25711263 [TBL] [Abstract][Full Text] [Related]
13. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918 [TBL] [Abstract][Full Text] [Related]
14. Good response to tolvaptan shortens hospitalization in patients with congestive heart failure. Kogure T; Jujo K; Hamada K; Saito K; Hagiwara N Heart Vessels; 2018 Apr; 33(4):374-383. PubMed ID: 29128962 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP; J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023 [TBL] [Abstract][Full Text] [Related]
16. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial. Shanmugam E; Doss CR; George M; Jena A; Rajaram M; Ramaraj B; Anjaneyan K; Kanagesh B Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648 [TBL] [Abstract][Full Text] [Related]
17. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. Matsue Y; Suzuki M; Seya M; Iwatsuka R; Mizukami A; Nagahori W; Ohno M; Matsumura A; Hashimoto Y J Cardiol; 2013 Feb; 61(2):169-74. PubMed ID: 23159210 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854 [TBL] [Abstract][Full Text] [Related]
19. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504 [TBL] [Abstract][Full Text] [Related]
20. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C; JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]